GleamWall
中文EN

LXEO Lexeo Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1907108 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-0.3%
TTM EPS YoY54.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-62.4%
ROA-54.3%
ROIC (approx.)-88.6%
Asset turnover—

Leverage & solvency

Liabilities / assets11.2%
Debt / equity0.00x
Current ratio8.69x
Interest coverage-1,807.43x

Cash quality & payout

Operating cash flow / net income0.83x
Accruals ratio-9.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$34.50M$19.03M$15.70M$16.21M$15.70M$14.72M$17.17M$18.37M
SG&A expense$5.90M$8.99M$6.63M$6.91M$5.95M$15.97M$16.63M$9.02M
Operating income-$40.40M-$28.02M-$22.33M-$23.12M-$21.65M-$30.69M-$33.80M-$27.38M
Interest expense$12,000$14,000$17,000$20,000$22,000$25,000$28,000$30,000
Pretax income-$38.30M-$25.87M-$20.20M-$20.63M-$20.28M-$26.10M-$32.66M-$25.92M
Net income-$38.30M-$25.87M-$20.20M-$20.92M-$20.28M-$26.10M-$32.66M-$25.92M
EBITDA-$40.31M-$27.95M-$22.26M-$23.04M-$21.57M-$30.63M-$33.74M-$27.31M
EPS (basic)-0.43-0.30-0.25—-0.33-0.60-0.99—
EPS (diluted)-0.43-0.30-0.25—-0.33-0.60-0.99—
Weighted avg. shares (diluted)88.68M85.63M81.18M—60.98M43.57M33.11M—
Balance sheet
Cash & equivalents$90.22M$92.83M$71.77M$63.00M$44.24M$38.73M$32.16M$38.27M
Short-term investments$104.56M$118.87M$121.28M$118.77M$81.77M$97.41M$70.92M$86.50M
Current assets$204.93M$217.91M$200.86M$188.39M$127.79M$140.06M$105.27M$126.12M
PP&E, net$1.73M$1.12M$1.10M$1.14M$1.23M$1.11M$1.04M$1.03M
Total assets$243.92M$254.90M$250.36M$268.69M$143.84M$176.07M$125.69M$146.94M
Current liabilities$23.59M$15.69M$14.19M$16.81M$17.27M$31.59M$30.82M$22.85M
Total liabilities$27.23M$19.84M$18.86M$22.02M$23.01M$37.85M$37.58M$30.10M
Shareholders' equity$216.69M$235.06M$231.50M$246.67M$120.83M$138.22M$88.11M$116.84M
Shares outstanding82.79M78.62M74.09M73.00M54.93M54.00M33.19M33.07M
Cash flow statement
Operating cash flow-$28.56M-$17.60M-$21.14M-$20.08M-$29.55M-$27.22M-$21.72M-$28.33M
Capital expenditure$298,000$7,000$35,000$0$289,000——$0
Free cash flow-$28.86M-$17.60M-$21.18M-$20.08M-$29.84M——-$28.33M
Investing cash flow$11.92M$14.26M$27.46M-$101.69M$35.01M-$39.17M$15.60M-$93.58M
Financing cash flow$14.03M$24.40M$2.45M$143.77M$52,000$72.96M$11,000-$97,000
Depreciation & amortization$86,000$74,000$73,000$73,000$73,000$62,000$60,000$75,000
Stock-based compensation$3.69M$5.69M$2.75M$2.71M$2.65M$3.07M$3.70M$3.51M

Free plan shows the latest 8 periods; Pro shows all 19 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.